



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

ZNHIT1 siRNA (m): sc-155809

BACKGROUND

ZNHIT1 (zinc finger, HIT-type containing 1), also known as CG11 (cyclin-G1-binding protein 1), p18 hamlet or ZNFN4A1 (zinc finger protein subfamily 4A member 1), is a 154 amino acid protein that plays a role in the induction of p53-mediated apoptosis. A member of the ZNHIT1 family, ZNHIT1 contains one HIT-type zinc finger and interacts with p38. ZNHIT1 undergoes post-translational phosphorylation and is encoded by a gene that maps to human chromosome 7q22.1, which houses over 1,000 genes and comprises nearly 5% of the human genome. Chromosome 7 has been linked to osteogenesis imperfecta, Pendred syndrome, lissencephaly, citrullinemia and Shwachman-Diamond syndrome. The deletion of a portion of the q arm of chromosome 7 is associated with Williams-Beuren syndrome, a condition characterized by mild mental retardation, an unusual comfort and friendliness with strangers and an elfin appearance.

REFERENCES

1. Tspouras, P., Myers, J.C., Ramirez, F. and Prockop, D.J. 1983. Restriction fragment length polymorphism associated with the *pro α 2(I)* gene of human type I procollagen. Application to a family with an autosomal dominant form of osteogenesis imperfecta. *J. Clin. Invest.* 72: 1262-1267.
2. Iwasaki, S., Usami, S., Abe, S., Isoda, H., Watanabe, T. and Hoshino, T. 2001. Long-term audiological feature in Pendred syndrome caused by PDS mutation. *Arch. Otolaryngol. Head Neck Surg.* 127: 705-708.
3. Cai, Y., Jin, J., Florens, L., Swanson, S.K., Kusch, T., Li, B., Workman, J.L., Washburn, M.P., Conaway, R.C. and Conaway, J.W. 2005. The mammalian YL1 protein is a shared subunit of the TRRAP/TIP60 histone acetyltransferase and SRCAP complexes. *J. Biol. Chem.* 280: 13665-13670.
4. Reiner, O., Sapoznik, S. and Sapir, T. 2006. Lissencephaly 1 linking to multiple diseases: mental retardation, neurodegeneration, schizophrenia, male sterility, and more. *Neuromolecular Med.* 8: 547-565.
5. Gilbert-Dussardier, B. 2006. Williams-Beuren syndrome. *Rev. Prat.* 56: 2102-2106.
6. Sjöblom, T., Jones, S., Wood, L.D., Parsons, D.W., Lin, J., Barber, T.D., Mandelker, D., Leary, R.J., Ptak, J., Silliman, N., Szabo, S., Buckhaults, P., Farrell, C., Meeh, P., Markowitz, S.D., Willis, J., Dawson, D., et al. 2006. The consensus coding sequences of human breast and colorectal cancers. *Science* 314: 268-274.
7. Lafarga, V., Cuadrado, A. and Nebreda, A.R. 2007. p18^{Hamlet} mediates different p53-dependent responses to DNA-damage inducing agents. *Cell Cycle* 6: 2319-2322.
8. Cuadrado, A., Lafarga, V., Cheung, P.C., Dolado, I., Llanos, S., Cohen, P. and Nebreda, A.R. 2007. A new p38 MAP kinase-regulated transcriptional coactivator that stimulates p53-dependent apoptosis. *EMBO J.* 26: 2115-2126.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

CHROMOSOMAL LOCATION

Genetic locus: *Znhit1* (mouse) mapping to 5 G2.

PRODUCT

ZNHIT1 siRNA (m) is a target-specific 19-25 nt siRNA designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see ZNHIT1 shRNA Plasmid (m): sc-155809-SH and ZNHIT1 shRNA (m) Lentiviral Particles: sc-155809-V as alternate gene silencing products.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

ZNHIT1 siRNA (m) is recommended for the inhibition of ZNHIT1 expression in mouse cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor ZNHIT1 gene expression knockdown using RT-PCR Primer: ZNHIT1 (m)-PR: sc-155809-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.